AOP HEALTH INKS AGREEMENT WITH LEUKOS BIOTECH FOR LEUKEMIA TREATMENT

KUALA LUMPUR, Aug 1 (Bernama) -- European pioneer for integrated therapies for rare diseases and in critical care, the AOP Health Group has signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute in early July.

The agreement signed covers the option for the development of newly discovered chemical substance within any treatable indication, not limited to oncological or rare diseases, according to a statement.

At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Both are special disease types of leukemia that often start in the bone marrow.

Chief business officer of AOP Orphan Pharmaceuticals GmbH, a member of AOP Health, Agnes Kohl said: “Based on positive data, our plan is to expand the development for further orphan indications even outside of AML and MDS at a later stage.

“With this agreement, we may be able to broaden the portfolio within our therapeutic areas offering even more treatment options for patients.”

As AOP Health focuses on rare, hemato-oncological cancers and has many years of experience in the development and commercialisation of hemato-oncological treatments, the company will drive the further development of the substance in cooperation with Leukos based on a new mode of action.

The company focuses on research, development and global sales of innovative treatment solutions and specialises in therapies for rare diseases and intensive care.

-- BERNAMA